Active Ingredient History
Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta, a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acne Vulgaris (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Autoimmune Diseases (Phase 2)
Behcet Syndrome (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 1)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 1)
Cryopyrin-Associated Periodic Syndromes (Phase 1/Phase 2)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetes Mellitus, Type 2 (Phase 2)
Esophageal Neoplasms (Phase 1)
Hypoglycemia (Phase 2)
Inflammation (Phase 1/Phase 2)
Osteoarthritis (Phase 2)
Pyoderma Gangrenosum (Phase 3)
Uveitis (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue